Transgene (Euronext : TNG)
Transgene is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer.
Investor Relations Contact
investorrelations@transgene.fr
Financial information
Key figures
| In € million except share and per share data | 2023 | 2022 | 2021 | 2020 | 2019 |
| Revenue | 7.9 | 10.3 | 17.4 | 9.9 | 13.7 |
| R&D Expense | -29.6 | -32.2 | -32.9 | -27.3 | -31.4 |
| G&A Expense | -7.0 | -7.9 | -7.4 | -6.5 | -7.1 |
| Net income (loss) | -22.3 | -32.8 | -19.5 | -17.2 | -18.8 |
| Net Cash Burn | -24.0 | -22.8 | -10.0 | -17.0 | -20.5 |
| Cash & Cash Equivalents | 15.7 | 26.8 | 49.6 | 26.3 | 43.3 |
| Earnings/Loss per Share (Basic) | -0.22 | -0.33 | -0.21 | -0.21 | -0.23 |
| Earnings/Loss per Share (Diluted) | -0.22 | -0.33 | -0.20 | -0.21 | -0.23 |
| Shares Outstanding | 100,852,742 | 100,204,071 | 97,771,334 | 83,841,334 | 83,265,464 |
Financial reports
| Years | Quarter | Interim | Registration Document | |||
|---|---|---|---|---|---|---|
| First | Second | Third | Fourth | |||
| 2024 | XBRL(fr) | |||||
| 2023 | XBRL(fr) Amendment(fr) | |||||
| 2022 | XBRL(fr) | |||||
| 2021 | XBRL(fr) | |||||
| 2020 | ||||||
| 2019 | ||||||
| 2018 | ||||||
| 2017 | ||||||
| 2016 | ||||||
| 2015 | ||||||
| 2014 | ||||||
Regulated information
Monthly information on shares outstanding and voting rights (in French)
Share buyback program (in French)
Liquidity contract related information
Half-year report on the Transgene liquidity contract
- 2024: at December 31, 2024; at June 30, 2024
- 2023: at December 31, 2023; at June 30, 2023
- 2022: at December 31, 2022; at June 30, 2022
- 2021: at December 31, 2021; at June 30, 2021
- 2020: at December 31, 2020; at June 30, 2020
- 2019: at December 31, 2019; at June 30, 2019
- 2018: at December 31, 2018; at June 30, 2018
- 2017: at December 31, 2017; at June 30, 2017
- 2016: at December 31, 2016; at June 30, 2016
Chairman’s report on corporate governance and internal controls
- Universal Registration Document 2024 (page 57)
- Universal Registration Document 2023 (page 63)
- Universal Registration Document 2022 (page 63)
- Universal Registration Document 2021 (page 73)
- Universal Registration Document 2024 (page 234)
- Universal Registration Document 2023 (page 246)
- Universal Registration Document 2022 (page 240)
- Universal Registration Document 2021 (page 220)
Annual General Meeting information
- May 5, 2023: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 25, 2022: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 26, 2021: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 27, 2020: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 22, 2019: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 23, 2018: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- June 8, 2017: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 24, 2016: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- June 11, 2015: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- June 18, 2014: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
Rights issue
Stock information
General
General
| Stock Market | Euronext Paris – Eurolist (compartiment C) |
| Reuters / Bloomberg | TRNG.PA / TNG.FP |
| ISIN Code | FR0005175080 |
| Total number of shares outstanding | 132,293,932 |
| Initial Public Offering (IPO) | March 26, 1998 |
| Local Sector Index | Next Biotech |
| Financial Year Ends | December 31 |
Analysts
| Company | Analyst | Phone | |
|---|---|---|---|
| Cantor Fitzgerald | Brandon Folkes | brandon.folkes@cantor.com | +1 212-294-8081 |
| Intron Health | Naresh Chouhan | naresh@intronhealthresearch.com | +44 207 375 9143 |
| Invest Securities | Jamila El Bougrini | jelbougrini@invest-securities.com | +33 (0)1 44 88 88 09 |
| Kempen & Co. | Suzanne van Voorthuizen | suzanne.vanvoorthuizen@kempen.com | +31 (0)20 348 8484 |
| Oddo BHF | Martial Descoutures | martial.descoutures@oddo-bhf.com | +33 (0)1 44 51 85 00 |
Any opinions, forecasts, estimates, projections or predictions regarding Transgene’s performance made by the analysts are theirs alone and do not necessarily represent the opinions, forecasts, estimates, projections or predictions of Transgene or its management. By providing the names of the analysts or certain information from them, Transgene does not imply its endorsement of or concurrence with their reports, conclusions or recommendations. Transgene assumes no liability for the accuracy of such information and undertakes no obligation to update it.
Investor Events & Presentations
Financial calendar
- March 27, 2024 - 2023 Fiscal Year Results
- May 14, 2024 - First Quarter 2024 Financial Results
- May 15, 2024 - Annual Shareholders’ Meeting
- September 24, 2024 - First Half 2024 Financial Results
- November 7, 2024 - Third Quarter 2024 Financial Results
- April 24, 2025 - First-Quarter 2025 Financial Results
Investor events
- April 1, 2025 - Investor Access Event (Paris) – April 1, 2025
- April 2, 2025 - Van Lanschot Kempen Life Sciences Conference (Amsterdam, Netherlands)- April 2, 2025
Annual General Meeting
Annual General Meeting of May 15, 2025
2025 ORDINARY AND EXTRAORDINARY MEETING
Location TRANSGENE 400 boulevard Gonthier d’Andernach – Parc d’Innovation 67400 ILLKIRCH-GRAFFENSTADEN – FRANCE
Date and Time 15 May 2025 at 10 am
– Retransmission (live and deferred) Webcast link to French language conference call
Documents:
- Notice of the 2025 General Shareholder’s Meeting
- French BALO publication, including resolutions (in French) and its corrigendum
- Presentation on draft resolutions
- Ballot (in French) and corrigendum
- Information regarding the total number of the outstanding shares and voting rights of the Company (Article R. 225-73-1 du French Commercial code)
- Universal Registration Document 2024
- Results of the vote (in French)
Availability of statutory auditors’ reports:
